Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences announces strategic expansion of ART27.13 development targeting preservation of muscle mass in patients receiving GLP-1 receptor agonist therapy. Supported by clinical and preclinical data, patent filing, and initiation of new studies, the company aims to position ART27.13 as a differentiated companion therapy in the fast-growing…